Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
First-in-Human Data from Ph 1 Trial of GTA182 in MTAP-Deleted Advanced NSCLC presented December 9, 2025
Clinically Meaningful OS Benefit for Gotistobart in Patients with Previously Treated Squamous NSCLC Announced December 9, 2025
Preliminary Ph 2 Data for Silevertinib in 1L NSCLC and Plans for Ph 2 Trial of Silevertinib in GBM Announced December 9, 2025
Ph 3 Trial of Sac-TMT in Combination with KEYTRUDA as 1L Treatment for PD-L1-Positive NSCLC Met Primary Endpoint December 2, 2025
Clinical results of glecirasib in combination with JAB-3312 (sitneprotafib) in KRAS G12C–mutated NSCLC published in The Lancet Respiratory Medicine December 2, 2025
HREC provides human ethics approval for HARNESS-1 Ph 1a/b trial of RC220 in patients with EGFR-mutated NSCLC December 2, 2025
FDA grants accelerated approval to HYRNUO™ (sevabertinib) for patients with previously treated advanced HER2-mutant NSCLC November 24, 2025
Positive Recommendation from IDMC to Continue Pivotal Ph 3 ARTEMIA Trial Evaluating Tedopi® in NSCLC November 24, 2025
FDA Accepts NDA for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC November 24, 2025
Rolling Submission of NDA to FDA initiated for Zipalertinib for Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations November 24, 2025
European Commission Approves Subcutaneous Administration of KEYTRUDA® for All Adult Indications Approved in the European Union November 24, 2025
FDA Granted Fast Track Designation for AVZO-1418 for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC November 18, 2025
Enrollment Completed in SAFFRON Ph 3 Trial of ORPATHYS + TAGRISSO Combo in TAGRISSO-treated EGFRm, MET-overexpressed and/or amplified LA/M NSCLC patients November 10, 2025
GSK5764227 (GSK’227) received Orphan Drug Designation from EMA for the treatment of pulmonary NEC/SCLC November 4, 2025
DESTINY-Lung06 Ph 3 Trial of ENHERTU Initiated as 1L Therapy in Patients with HER2 Overexpressing Metastatic NonSquamous NSCLC November 4, 2025
Updated Elironrasib Safety & Efficacy Data in Patients with KRAS G12C NSCLC Following Treatment with a KRAS(OFF) G12C Inhibitor Presented October 29, 2025
BLA submission planned in Q4 2025 for Ivonescimab based on HARMONi Global Ph 3 Study Results October 29, 2025
First Patient Enrolled in Ph 1 Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 October 21, 2025
Ivonescimab Global Ph 3 Development Program with HARMONi-GI3 Study expanded in 1L CRC October 21, 2025
FDA feedback provided regarding the successful completion of Project Optimus requirements and agreement on 30mg as the optimal biological dose for eftilagimod alfa (efti) October 21, 2025
